MonumenTAL-6

A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

Near Add Your Location

Regions Hospital
St. Paul, MN
  • Accepting patients
Cleveland Clinic - Taussig Cancer Center
Taussig Cancer Institute
Cleveland, OH
  • Accepting patients
UPMC Hillman Cancer Center
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, PA
  • Accepting patients
Memorial Cancer Institute
Memorial Regional Hospital
Hollywood, FL
  • Accepting patients
Norton Cancer Institute (St. Matthews)
St. Matthews Campus
Louisville, KY
  • Accepting patients
Ascension Providence Hospital (Southfield)
St. John Newland Medical Associates
Southfield, MI
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.